PROCEPT is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Company profile
Ticker
PRCT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Haemonetics • Hill-Rom • Nuvasive ...
SEC CIK
Corporate docs
IRS number
260199180
PRCT stock data
Analyst ratings and price targets
Current price
Average target
$49.00
Low target
$43.00
High target
$55.00
Truist Securities
Maintains
$55.00
Wells Fargo
Maintains
$43.00
Latest filings (excl ownership)
8-K
PROCEPT BioRobotics Announces Preliminary Fourth Quarter and Fiscal Year 2022 Revenue
9 Jan 23
10-Q
2022 Q3
Quarterly report
4 Nov 22
8-K
PROCEPT BioRobotics Reports Third Quarter 2022 Financial Results and Increases 2022 Revenue Guidance
3 Nov 22
8-K
Entry into a Material Definitive Agreement
11 Oct 22
10-Q
2022 Q2
Quarterly report
5 Aug 22
8-K
PROCEPT BioRobotics Reports Second Quarter 2022 Financial Results and Increases 2022 Revenue Guidance
4 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 22
8-K
Regulation FD Disclosure
13 May 22
10-Q
2022 Q1
Quarterly report
6 May 22
S-8
Registration of securities for employees
6 May 22
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 253.03 mm | 253.03 mm | 253.03 mm | 253.03 mm | 253.03 mm | 253.03 mm |
| Cash burn (monthly) | 6.86 mm | 5.69 mm | 7.37 mm | 6.04 mm | (no burn) | 1.50 mm |
| Cash used (since last report) | 28.85 mm | 23.90 mm | 30.98 mm | 25.41 mm | n/a | 6.31 mm |
| Cash remaining | 224.18 mm | 229.13 mm | 222.05 mm | 227.63 mm | n/a | 246.72 mm |
| Runway (months of cash) | 32.7 | 40.3 | 30.1 | 37.7 | n/a | 164.3 |
Institutional ownership, Q3 2022
72.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 93 |
| Opened positions | 14 |
| Closed positions | 15 |
| Increased positions | 38 |
| Reduced positions | 30 |
| 13F shares | Current |
|---|---|
| Total value | 1.34 bn |
| Total shares | 32.25 mm |
| Total puts | 176.10 k |
| Total calls | 55.10 k |
| Total put/call ratio | 3.2 |
| Largest owners | Shares | Value |
|---|---|---|
| CPMG | 9.06 mm | $375.43 mm |
| FMR | 6.46 mm | $267.68 mm |
| Vanguard | 2.84 mm | $117.69 mm |
| T. Rowe Price Investment Management | 2.57 mm | $106.71 mm |
| BLK Blackrock | 1.81 mm | $75.00 mm |
| T. Rowe Price | 1.07 mm | $44.41 mm |
| Driehaus Capital Management | 870.87 k | $36.11 mm |
| JNJ Johnson & Johnson | 863.91 k | $35.82 mm |
| BLVGF Bellevue | 589.26 k | $24.43 mm |
| Geode Capital Management | 528.03 k | $21.89 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 4 Jan 23 | Hisham Shiblaq | Common Stock | Sell | Dispose S | No | Yes | 39.7447 | 466 | 18.52 k | 27,275 |
| 3 Jan 23 | Hisham Shiblaq | Common Stock | Sell | Dispose S | No | Yes | 41.7397 | 6,306 | 263.21 k | 27,741 |
| 3 Jan 23 | Hisham Shiblaq | Common Stock | Sell | Dispose S | No | Yes | 40.4687 | 5,421 | 219.38 k | 34,047 |
| 3 Jan 23 | Hisham Shiblaq | Common Stock | Sell | Dispose S | No | Yes | 39.7594 | 9,736 | 387.10 k | 39,468 |
| 27 Dec 22 | Alaleh Nouri | Common Stock | Sell | Dispose S | No | Yes | 40.4665 | 1,588 | 64.26 k | 4,062 |
| 27 Dec 22 | Alaleh Nouri | Common Stock | Sell | Dispose S | No | Yes | 41.3599 | 1,476 | 61.05 k | 5,650 |
| 19 Dec 22 | Alaleh Nouri | Common Stock | Sell | Dispose S | No | Yes | 43.0783 | 11,489 | 494.93 k | 7,126 |
| 19 Dec 22 | Alaleh Nouri | Common Stock | Sell | Dispose S | No | Yes | 43.4341 | 8,511 | 369.67 k | 18,615 |
| 16 Dec 22 | Alaleh Nouri | Common Stock | Sell | Dispose S | No | Yes | 41.9674 | 20,000 | 839.35 k | 27,126 |
| 5 Dec 22 | Antal Rohit Desai | Common Stock | Other | Dispose J | Yes | No | 0 | 1,726,534 | 0.00 | 5,029,869 |
News
Expert Ratings for PROCEPT BioRobotics
31 Jan 23
Truist Securities Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $55
31 Jan 23
Wells Fargo Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $43
12 Jan 23
Expert Ratings for PROCEPT BioRobotics
12 Dec 22
Wells Fargo Maintains Overweight on PROCEPT BioRobotics, Raises Price Target to $52
12 Dec 22